Innate Pharma S.A. (IPHA)

Innate Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	6	12.62	51.9	49.58	12.11	56.16
Other Revenue	6.64	7.5	9.74	8.09	12.59	13.62
Revenue	12.64	20.12	61.64	57.67	24.7	69.77
Revenue Growth (YoY)	-62.60%	-67.36%	6.88%	133.47%	-64.59%	-18.34%
Cost of Revenue	43.42	51.98	56.02	51.66	47	49.71
Gross Profit	-30.79	-31.86	5.62	6.01	-22.3	20.07
Selling, General & Admin	19.9	19.72	18.29	22.44	25.52	18.99
Operating Expenses	19.9	19.72	18.29	22.44	25.52	18.99
Operating Income	-50.69	-51.58	-12.67	-16.43	-47.83	1.08
Interest Expense	-0.5	-0.57	-0.64	-0.29	-0.31	-0.34
Interest & Investment Income	1.96	2.44	3.18	0.55	0.33	0.56
Currency Exchange Gain (Loss)	2.2	-1.75	0.91	0.83	1.25	-1.58
Other Non Operating Income (Expenses)	0.98	1.98	1.65	-1.63	1.08	-0.55
EBT Excluding Unusual Items	-46.05	-49.47	-7.57	-16.97	-45.48	-0.83
Asset Writedown	-	-	-	-41	-	-
Pretax Income	-46.05	-49.47	-7.57	-57.97	-45.48	-0.83
Earnings From Continuing Operations	-46.05	-49.47	-7.57	-57.97	-45.48	-0.83
Earnings From Discontinued Operations	-	-	-	-0.13	-7.33	-63.16
Net Income	-46.05	-49.47	-7.57	-58.1	-52.81	-63.98
Net Income to Common	-46.05	-49.47	-7.57	-58.1	-52.81	-63.98
Shares Outstanding (Basic)	84	81	80	80	80	79
Shares Outstanding (Diluted)	84	81	80	80	80	79
Shares Change (YoY)	4.15%	0.74%	1.02%	0.12%	0.77%	17.97%
EPS (Basic)	-0.55	-0.61	-0.09	-0.73	-0.66	-0.81
EPS (Diluted)	-0.55	-0.61	-0.09	-0.73	-0.66	-0.81
Free Cash Flow	-41.26	-7.29	-32.91	-19.69	-59.39	-52.67
Free Cash Flow Per Share	-0.49	-0.09	-0.41	-0.25	-0.75	-0.67
Gross Margin	-243.65%	-158.34%	9.12%	10.42%	-90.28%	28.76%
Operating Margin	-401.15%	-256.32%	-20.55%	-28.48%	-193.60%	1.55%
Profit Margin	-364.44%	-245.87%	-12.28%	-100.74%	-213.78%	-91.70%
Free Cash Flow Margin	-326.54%	-36.22%	-53.39%	-34.14%	-240.40%	-75.49%
EBITDA	-49.77	-50.27	-8.53	-12.02	-43.23	13.31
EBITDA Margin	-	-249.86%	-13.84%	-20.84%	-174.99%	19.07%
D&A For EBITDA	0.92	1.3	4.14	4.41	4.6	12.23
EBIT	-50.69	-51.58	-12.67	-16.43	-47.83	1.08
EBIT Margin	-	-256.32%	-20.55%	-28.48%	-193.60%	1.55%
Revenue as Reported	12.64	20.12	61.64	57.67	24.7	69.77

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q